A phase II, open-label, multicenter clinical trial of pegylated liposomal doxorubicin (Caelyx®) as primary treatment for patients with breast cancer and a history of heart disease or age over 65 years
CAPRICE (SOLTI-0702)
Clinical Trial Program
A phase II, open-label, multicenter clinical trial of pegylated liposomal doxorubicin (Caelyx®) as primary treatment for patients with breast cancer and a history of heart disease or age over 65 years
Phase II
Status
Finished
Tumour subtype:
TNBC
Scenario
Neoadyuvante
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Juan Miguel Gil Gil, MD (Institut Català d'Oncologia - ICO Duran i Reynals)
Sites
